reMYND drives the development of disease-modifying treatments against Alzheimer’s, Parkinson’s, Diabetes and other protein misfolding disorders

…through two independently managed business units:

The in-vivo Contract Research Organization (CRO) helps its clients to assess the pharmacokinetics and -dynamics of their experimental treatments against Alzheimer's disease. The main focus is on efficacy testing of candidate drugs in reMYND’s proprietary Alzheimer mouse models expressing the clinical APP-London allele as single transgene or in combination with clinical alleles of human PS1 and TAU.

The Drug Discovery and Development Unit (DDD) focuses on disease-modifying treatments against protein-misfolding disorders, such as Alzheimer's disease (tau), Parkinson's disease (α-synuclein), and Diabetes.


In addition, reMYND grants licenses and markets commercial kits of RadarScreen, a technology for rapid and cost-effective identification of genotoxic liabilities in early stage drug discovery.


reMYND has been substantially supported by grants from IWT and from The Michael J Fox Foundation.